Evren Technologies, Inc
Advancing PTSD Treatment with an FDA Breakthrough Device
Gainesville, FL
Biotechnology
Health Tech
Evren Technologies is developing a discrete earbud that utilizes a groundbreaking treatment for PTSD to help people easily manage their symptoms and improve outcomes. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.*
$213,152
raised
84
Investors
$15.1M
Valuation
$6.65
Price per Share
$399.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
3
Days Left
Rewards
Get rewarded for investing more into Evren Technologies, Inc:
$399+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,000+
Investment
Investor | $1,000+
Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).
$5,000+
Investment
Watt | $5,000+
Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
$10,000+
Investment
Franklin | $10,000+
Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).
$25,000+
Investment
Edison | $25,000+
Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).
$50,000+
Investment
Tesla | $50,000+
Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).
Reasons to Invest
FDA Breakthrough Device Designation | Evren’s device, the Phoenix®, was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of PTSD. Evren is also the recipient of a SBIR from the National Institute of Mental Health (NIMH) and a contract from the Army Medical Research and Development Command
Novel Technology for a Massive Growing Market | PTSD is an underserved, $22.5 Billion-dollar market with 66% of those suffering currently seeking new treatment solutions. 15 Million Americans will suffer from PTSD in any given year and over 60 million had PTSD during the height of the COVID shutdown.**
High User Satisfaction and Low Dropout Rates | 100% of Phoenix® users wanted to continue using the device after the pilot trial and all of them were willing to pay out-of-pocket for it.
Evren Technologies currently has a working prototype of the Phoenix® earbud and a beta version of the accompanying app
*Information based on internal research with resources provided by the National Center for PTSD ( source)
A Groundbreaking Treatment for PTSD
PTSD affects millions of Americans, but current treatments simply aren’t working. Sixty-six percent of those suffering from PTSD—which includes 20% of veterans, first responders, and front-line nurses, and 6% of the overall population—are actively seeking out new solutions (source, source, source). Unfortunately, the medical system still relies primarily on antidepressants and therapy, which offer unreliable treatment, are often accompanied by serious side effects including increased suicidality, and can even worsen symptoms. As a result, dropout rates are high and improvement rates are low.
This is why we’re creating the Phoenix, an innovative earbud device that is capable of integrating smoothly into a user’s lifestyle, providing on-the-go treatment that empowers patients to control their own PTSD. The Phoenix will provide personalized levels of vagal nerve stimulation to reduce PTSD symptom severity and improve quality of life without the harmful side effects seen with prescription drugs.
The stimulation provided through our patented closed-loop algorithm will offers a huge improvement over current treatments, with clinical results that garnered an FDA Breakthrough Device Designation. To date, 100% of users wanted to continue usage past the end of the trial, 100% were willing to pay out-of-pocket for the device, and the vast majority of users would recommend the device to a friend (95.6 Net Promoter Score).
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
The device reduces PTSD severity, which includes symptoms such as depression, anxiety, insomnia, nightmares & flashbacks, social avoidance, and suicidality — and does so with no significant side effects. The Phoenix was recently awarded Breakthrough Device Designation by the FDA based on early clinical data, and we’re now ready to launch it into the next phase of development as we look to serve those chronically suffering from PTSD.
The Problem
New treatments are needed to address the challenges of PTSD
According to the National Center for PTSD, about 15 million adults in the US suffer from PTSD during a typical year, and the pandemic has been far from typical. Rates among veterans, EMTs, nurses, police, and firefighters are the highest, at around 20%, though an overall 6% of the American population will have PTSD at some point in their lives. (source)
While traditionally associated with veterans, PTSD can affect anyone who has experienced trauma, and significantly increases the likeliness of suicide (13x more likely from those suffering from PTSD; source). The prevalence of domestic violence and sexual abuse also contribute to higher rates of PTSD among women versus men (8% vs. 4%). PTSD also comes with multiple serious comorbidities, including depression and substance abuse. (source)
(source)
Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. The primary treatment option is antidepressants, which can cause increased suicidality and are intended only for short-term use.
(source)
Therapy, another common treatment in the patient roadmap, is more time and resource-intensive than many people can afford, and still lacks proper research, phenotyping, and individualization—oftentimes worsening symptoms. Researchers and academics agree that current therapies are inadequate, indicating a pressing need for new approaches to the issue.
The Solution
Evren's Phoenix earbud will put the power of treatment in the hands of the user
Evren’s Phoenix earbud will treat PTSD by stimulating the vagus nerve with a light electrical tingle, providing personalized dosing based on users’ stress levels. Vagal nerve stimulation is directly related to the balance of calm and stress in the body and influences how we store and retrieve fearful memories.
If you are interested in more information about the science behind the Phoenix vagal nerve stimulation, visit Evren’s website. (www.RiseAbovePTSD.com)
By putting the power of treatment in the hands of the user, the Phoenix earbud will provide an option for discreet treatment that can be used for both managing daily symptoms and navigating high-stress situations. The results of our clinical pilot trial showed a reduction in PTSD symptom severity (measured through CAPS-5), improved quality of life (PROMIS-29), and no significant side effects. Additionally, the earbud will pair with a free app, where patients can track symptoms, record sleep activity, and identify triggers.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
We plan to sell our Phoenix device via three channels: A direct-to-consumer (DTC) digital ad campaign for early movers, sales to the Department of Veterans Affairs, and finally reimbursed sales through healthcare providers. Our current DTC model will begin at $99/mo for the first year (until the earbud is paid off - Rx required), then continuing at $49/mo to cover additional supplies and support.
In addition to product sales, we plan to leverage our growing database of de-identified data, which can be used to support advancements in the understanding and treatment of PTSD, while also making us a potential acquisition target for health management companies. Please note there is no guarantee on future results. Refer to our Offering Materials and Risk Factors for more information regarding our offering.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Evren has developed a connected ecosystem to support, treat, and connect patients with clinicians
Evren is not only offering a device for the treatment of PTSD, but an entire platform to support, treat, and connect patients with clinicians. As an organization, we are highly focused on the needs of the patient. As part of our initial ethnographic research with patients and clinicians, we discovered that one of the first things patients’ are asked to do is to start tracking their symptoms to establish a baseline and allow them to track progress. Unfortunately there was no app on the market to specifically help users with PTSD actively track their symptoms day-by-day. Since then, the Phoenix PTSD App has evolved to offer further functionality to support patients and clinicians.
With an earbud that collects biosignals for our closed-loop algorithm, and an app collecting patient symptoms, we can do two major things:
- Create a portal where clinicians, once given permission by their patient, can track patient’s progress and use insights to develop better therapy plans.
- Create a HIPAA-compliant database of de-identified data (data with no personal information that could be used to identify an individual) to learn about PTSD and help develop better solutions for the future.
The Market
Failing to effectively treat millions of Americans means an unmet need and massive market
PTSD is an enormous global market, valued at $22.5B in the US alone.* In the US, there are approximately 15M cases of PTSD each year, with 66% of people affected by PTSD still looking for treatment solutions. PTSD affects a wide-ranging demographic,and the number of those affected has spiked dramatically during the ongoing COVID pandemic to over 60 Million Americans.
*Information based on internal research done by Evren Technologies
*Information based on internal research done by Evren Technologies
(source)
Based on our knowledge, no existing wearable stimulation device has received FDA approval for the treatment of PTSD, and not one includes Evren’s patented closed-loop stimulation. Other wearable neuromodulation devices created for use as a PTSD treatment rely on old technology and/or poor design, resulting in underwhelming results. Evren’s Phoenix device leverages improvements on existing technologies, refining the user experience and outcomes.
Antidepressants, a more common treatment option, are intended only for short-term use, while therapy can make symptoms worse, especially if a patient is unable to complete their full treatment. Other PTSD treatments, such as psychedelics, are still actively being explored and have yet to be cleared.
Additionally, these treatments are only proving effective when paired with exposure therapy, meaning patients unwilling to go through therapy will not be able to use and benefit from these solutions. Compared to these existing and developing standards of care, the Phoenix device has much lower side effects, higher response rates, and a lower dropout percentage.
Our Traction
FDA designation, NIMH funding, and excellent user feedback
Since Evren started in 2019, we’ve made incredible strides and have seen a phenomenal response from our initial users, including the completion of multiple iterations of our prototype as well as a clinical trial during the COVID-19 shutdown. Most significantly, we received Breakthrough Device Designation from the FDA based on our pilot trial results, indicating confidence that we may provide better treatment than the current standard of care in the serious, life threatening and chronic condition of PTSD.
We now have a working device and clinical evidence, and are nearly ready to launch the Phoenix® PTSD App. Our app allows users to document their symptoms on the go and helps them try to identify individualized triggers, functionality not provided by the VA’s PTSD Coach apps, the current market leader. Our next step is to launch the industrial design phase, enabling production of the fully miniaturized earbud, and from there, a pivotal trial for official FDA clearance.
*The above is a rendering of Evren's Phoenix app. Images feature a computer generated wireframe. Product is still currently under development.
The Phoenix has received a 95.6 Net Promoter Score, with 100% of users wanting to continue use past the end of their trial and 100% of users willing to pay a monthly out-of-pocket fee. Patients have truly connected with their Phoenix device experience. Here are some quotes from pilot trial participants:
*Testimonials may not be representative of the experience of other customers and are not a guarantee of future performance or success.
Evren has received $232,285 in PPP awards and EIDL loans. In addition, we accumulated $1.571M comprising $814,900 in two series of convertible notes, $140,000 in promissory notes issued to an officer, $10,000 in prize money for a video contest, and $256,000 in an NIH grant.
Why Invest
Working towards a better future for those suffering from PTSD
We envision a better future for those suffering from PTSD—though it doesn’t stop there. Our Phoenix earbud is an extremely scalable technology, with vagal nerve stimulation approved for the treatment of many other disorders, including epilepsy, opioid withdrawal, major depressive disorder, and migraines, with potential application for a longer list that includes anxiety, insomnia, and traumatic brain injury.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Join us on our mission to improve countless lives, enable a happier, healthier future, and empower patients to #RiseAbovePTSD.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Offering Summary
Company | : | Evren Technologies, Inc |
Corporate Address | : | 404 SW 140th Terrace, Suite 50, Gainesville, FL 32669 |
Offering Minimum | : | $9,994.95 |
Offering Maximum | : | $1,069,998.30 |
Minimum Investment Amount(per investor) | : | $399.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 1,503 |
Maximum Number of Shares Offered | : | 160,902 |
Price per Share | : | $6.65 |
Pre-Money Valuation | : | $15,085,870.80 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based
Friends and Family Early Birds
Invest within the first 72 hours and receive 15% bonus shares.
Early Bird Bonus
Invest within the first week (7 calendar days) and receive 10% bonus shares.
Amount-Based
Investor | $1,000+
Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).
Watt | $5,000+
Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
Franklin | $10,000+
Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).
Edison | $25,000+
Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).
Tesla | $50,000+
Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Evren Technologies, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.65 / share, you will receive 110 shares Common Stock, meaning you'll own 110 shares for $665. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Insider Investment Notice
Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$202,707.00
USD
$116,875.00
USD
Cash And Cash Equivalents
$64,269.00
USD
$13,388.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$436,215.00
USD
$514,900.00
USD
Long Term Debt
$150,000.00
USD
$150,000.00
USD
Revenues And Sales
$0.00
USD
$0.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
$14,956.00
USD
-$418,616.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
Awarded MTEC Grant!
6 days ago
Hello Evren Community!
We were awarded the prestigious Medical Technology Enterprise Consortium (Army in partnership with the DOD) grant for quality system implementation!
This grant will allow the advancement of PTSD treatment and related conditions through wearable neurostimulation products.
The Phoenix® will be a discrete earbud that utilizes our groundbreaking treatment for PTSD. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.
Please spread the word about our investment opportunity to your friends, family and network!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Evren’s CEO Webinar is Only 1 Day Away!
10 days ago
A final, friendly reminder that our webinar is only 1 day away! Hosted by Evren Technologies CEO Weaver Gaines, who is ready to answer all your investor questions!
Learn why you don’t want to miss out on this $22B market opportunity (bioelectronic medicine and PTSD)!
Join us live this Friday, June 17th, 2022 at 1:00 PM PST!
Our live Q&A investor webinar is tomorrow, so be sure to reserve your spot today!
Some perks for becoming an early investor are:
$1,000+ Investment- 50% off device
$5,000+ Investment - 5% bonus shares + 50% off device
$10,000+ Investment - 10% bonus shares + 50% off 2 devices
$25,000+ Investment - 20% bonus shares + 50% off 3 devices
$50,000+ Investment - 25% bonus shares + 50% off 4 devices
Sign up to register for our live webinar today! Please help spread the word by sharing this email with your network!
Visit our raise page on StartEngine to learn more!
Warmly,
Weaver Gaines
CEO
Evren Technologies
New York Times Mentions Evren Technologies!
10 days ago
Evren Technologies has some exciting news! Recently, Dr. Eric Porges was mentioned in a New York Times article featuring the revolutionary vagus nerve stimulation therapy.
The Phoenix is a noninvasive, portable device that delivers a light electrical tingle to your vagus nerve, inducing a calming effect shown to reduce symptoms of PTSD with no side effects.
Evren Technologies is changing how people recover from trauma, and we’re excited to pursue further research and development for this amazing new treatment.
We need investors like you to help us reach our goal of alleviating symptoms for the millions of people suffering from PTSD. The current treatment market for this industry is $22.5B a year and is still growing annually.
Help us make a real difference in PTSD research and help people around the world rise above PTSD.
You can become an early investor for as little as $399!
Visit our raise page on StartEngine to learn about more perks of becoming an early investor.
Warmly,
Weaver Gaines
CEO
Evren Technologies
Evren Invites You to Our Webinar June 17th!
13 days ago
We are thrilled to invite you to our live Q&A webinar one week away, hosted by Evren CEO Weaver Gaines!
Join us live on Friday, June 17th, at 1:00 PM PST!
There is only one week remaining to register for our investor webinar. I will be ready to discuss what makes Evren Technologies a great investment opportunity and answer all your questions!
Sign up to register for Evren’s investor Q&A webinar today!
I am looking forward to sharing with you the perks of becoming an early investor and how Evren Technologies can help millions of people struggling with persistent symptoms of PTSD!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Only 5 Days Remaining Until Evren’s Live Webinar!
16 days ago
We are thrilled to invite you to our live webinar this Friday, hosted by Evren CEO Weaver Gaines!
Join us live on Friday, June 17th, at 1:00 PM PST!
There are only 5 days left to register for our investor Q&A webinar. I will be ready to discuss why Evren Technologies is a great investment opportunity and answer all your questions!
Sign up to register for Evren’s investor Q&A webinar today!
I’m looking forward to sharing the benefits of becoming an early investor, and discussing how you can aid Evren Technologies’ mission to help millions of people struggling with persistent symptoms of PTSD!
Visit our raise page on StartEngine to learn more about our investor community!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Celebrating $200K Investments!
18 days ago
Hello Evren Community!
Now, this is something worth bragging about! The Evren team is ecstatic to announce we’ve reached $200K investments!
It can be tough living with PTSD. At Evren, we feel it is our mission to create solutions that work for people to easily manage their symptoms and improve outcomes. This is why we are developing a discrete earbud that will be a groundbreaking, non-drug treatment for PTSD!
Why should you invest?
Be a part of the PTSD global market valued at $20B+.
We're addressing the 15M Americans suffering from PTSD.
Successful, passionate management team with 100 years of combined experience.
We encourage all current investors to reinvest and to spread the word about our investment opportunity on StartEngine!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Less Than 2 Weeks Until Evren’s Informative CEO Webinar!
19 days ago
My name is Weaver Gaines, CEO of Evren Technologies. I will be hosting an informative investor Q&A webinar on Friday, June 17th, 2022 at 1:00 PM PST and invite you all to attend!
There are less than two weeks remaining until I go live to answer all your questions, so be sure to register today!
Evren Technologies is dedicated to developing our discrete earbud that utilizes a groundbreaking treatment to alleviate distressing symptoms of PTSD.
Supported by clinical evidence, the Phoenix earbud drastically improves both patient health and well-being with fewer side effects and higher patient engagement than currently available treatment options!
Millions of people struggle with persistent symptoms of PTSD.
The Phoenix was recently granted an FDA Breakthrough Device Designation for demonstrating the capability to significantly reduce PTSD symptoms and give people their lives back.
Register for our webinar here and please help spread the word!
Come prepared to ask questions by reading more about our goals by visiting our StartEngine raise page.
Together, we can empower patients to rise above PTSD!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Exclusive Investor Q&A Recap!
20 days ago
Evren Technologies Community,
Evren Technologies is on a mission to help people rise above PTSD.
We recently held an investor webinar where we shared the amazing results of our PTSD trial with the Phoenix device - which made the FDA award Evren a breakthrough device designation!!
In case you missed it, we encourage you to check out our recent webinar recap video!
If you have any questions that are still left unanswered, do not hesitate to reach out to our team! We will be more than happy to assist you.
If you haven’t already done so, we encourage you to reinvest and help us reach our milestones sooner.
Thank you for your continued support and belief in our mission!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Our Scientific Board of Advisors is Growing!
about 1 month ago
It is our pleasure to announce that Dr. J. Douglas Bremner has joined our Scientific Advisory Board. Dr. Bremner attended medical school at Duke University, followed by residency in Psychiatry and Nuclear Medicine at Yale. He is currently a professor of psychiatry and the director of the Emory Clinical Neuroscience Research Unit at Emory University School of Medicine. Dr. Bremner’s research has used neuroimaging and neurobiology measures to study PTSD related to combat and childhood abuse, and he has authored/co-authored over 200 peer reviewed articles. Evren Technologies is thrilled to have Dr. Bremner’s counsel as we work towards our goal: to relieve the suffering of millions with this disabling condition. We are confident that his advice will propel our Phoenix towards nothing less than groundbreaking improvements in the way we treat PTSD.
Warmly,
Weaver Gaines
CEO
Evren Technologies
Evren Technologies is Offering Bonus Shares!
about 2 months ago
Evren Technologies Community,
Ready to invest into Evren Technologies, Inc.?
We’ve designed a number of perks where you receive extra capital based on your investment amount - buy more shares, get more shares!
Here’s the list of perks that you can also find on our StartEngine raise page:
$399+ Investment - This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section on our raise page.
$1,000+ Investment (Investor) - Receive 50% off device purchase (coupon for use once the product is available on the market).
$5,000+ Investment (Watt) - Receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
$10,000+ Investment (Franklin) - Receive 10% bonus shares + 50% off 2 device purchases (coupon for use once the product is available on the market).
$25,000+ Investment (Edison) - Receive 20% bonus shares + 50% off 3 device purchases (coupon for use once the product is available on the market).
$50,000+ Investment (Tesla) - Receive 25% bonus shares + 50% off 4 device purchases (coupon for use once the product is available on the market).
What are you waiting for? Head over to our raise page and take advantage of this opportunity while time permits!
Our executive team would like to thank you in advance for your support.
Warmly,
Weaver Gaines
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}